Nanocomplexes for gene therapy of respiratory diseases: Targeting and overcoming the mucus barrier

DOI: 10.1016/j.pupt.2015.07.003
Pulmonary Pharmacology and Therapeutics, 2015, 34, 8-24.

#	Paper	IF	Citations
42	Advanced Therapeutic Strategies for Chronic Lung Disease Using Nanoparticle-Based Drug Delivery. *Journal of Clinical Medicine*, **2016**, 5,	5.1	61
41	Novel nanoparticle materials for drug/food delivery-polysaccharides. *ChemistrySelect*, **2016**, 1,	1.8	3
40	CFTR Modulators: Shedding Light on Precision Medicine for Cystic Fibrosis. *Frontiers in Pharmacology*, **2016**, 7, 275	5.6	79
39	8. Novel nanoparticle materials for drug/food delivery-polysaccharides. **2016**, 159-190		
38	Barriers to inhaled gene therapy of obstructive lung diseases: A review. *Journal of Controlled Release*, **2016**, 240, 465-488	11.7	57
37	Evaluation of polylactic acid nanoparticles safety using Drosophila model. *Nanotoxicology*, **2016**, 10, 1136-43	5.5	16
36	Potential and development of inhaled RNAi therapeutics for the treatment of pulmonary tuberculosis. *Advanced Drug Delivery Reviews*, **2016**, 102, 21-32	18.5	16
35	A branched TAT cell-penetrating peptide as a novel delivery carrier for the efficient gene transfection. *Biomaterials Research*, **2016**, 20, 28	16.8	22
34	Could recent advances in DNA-loaded nanoparticles lead to effective inhaled gene therapies?. *Nanomedicine*, **2016**, 11, 193-6	5.6	6
33	Building dry powder formulations using supercritical CO2 spray drying. *Current Opinion in Green and Sustainable Chemistry*, **2017**, 5, 12-16	7.9	14
32	Polymeric drug delivery micelle-like nanocarriers for pulmonary administration of beclomethasone dipropionate. *Colloids and Surfaces B: Biointerfaces*, **2017**, 151, 206-214	6	23
31	New perspectives in nanotherapeutics for chronic respiratory diseases. *Biophysical Reviews*, **2017**, 9, 793-803	3.7	36
30	Nano into Micro Formulations of Tobramycin for the Treatment of Pseudomonas aeruginosa Infections in Cystic Fibrosis. *Biomacromolecules*, **2017**, 18, 3924-3935	6.9	15
29	Inhaled gene delivery: a formulation and delivery approach. *Expert Opinion on Drug Delivery*, **2017**, 14, 319-330	8	24
28	Polyanion-tobramycin nanocomplexes into functional microparticles for the treatment of Pseudomonas aeruginosa infections in cystic fibrosis. *Nanomedicine*, **2017**, 12, 25-42	5.6	7
27	Nanotechnology in Drug Discovery and Development. **2017**, 264-295		0
26	Biomarkers of Inflammation and Remodelling in Cystic Fibrosis. *Clinical Immunology, Endocrine and Metabolic Drugs*, **2017**, 3,		3

25	Polyaspartamide-Based Nanoparticles Loaded with Fluticasone Propionate and the In Vitro Evaluation towards Cigarette Smoke Effects. *Nanomaterials*, **2017**, 7,	5.4	7
24	Efficacy and safety concerns over the use of mucus modulating agents for drug delivery using nanoscale systems. *Advanced Drug Delivery Reviews*, **2018**, 124, 184-192	18.5	13
23	Biomimetics of the pulmonary environment : A microfluidics perspective. *Biomicrofluidics*, **2018**, 12, 042209	3.2	30
22	Nanoparticle delivery of grape seed-derived proanthocyanidins to airway epithelial cells dampens oxidative stress and inflammation. *Journal of Translational Medicine*, **2018**, 16, 140	8.5	31
21	Effective silencing of ENaC by siRNA delivered with epithelial-targeted nanocomplexes in human cystic fibrosis cells and in mouse lung. *Thorax*, **2018**, 73, 847-856	7.3	34
20	Advances in nanotechnology and asthma. *Annals of Translational Medicine*, **2019**, 7, 180	3.2	17
19	Solid lipid nanoparticles made of self-emulsifying lipids for efficient encapsulation of hydrophilic substances. **2019**,		6
18	Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles. *Signal Transduction and Targeted Therapy*, **2019**, 4, 33	21	196
17	Self-assembled peptide-poloxamine nanoparticles enable in vitro and in vivo genome restoration for cystic fibrosis. *Nature Nanotechnology*, **2019**, 14, 287-297	28.7	51
16	Cystic Fibrosis: Proteostatic correctors of CFTR trafficking and alternative therapeutic targets. *Expert Opinion on Therapeutic Targets*, **2019**, 23, 711-724	6.4	6
15	Nanometric ion pair complexes of tobramycin forming microparticles for the treatment of Pseudomonas aeruginosa infections in cystic fibrosis. *International Journal of Pharmaceutics*, **2019**, 563, 347-357	6.5	2
14	Harnessing Stem Cells and Neurotrophic Factors with Novel Technologies in the Treatment of Parkinsonâs Disease. *Current Stem Cell Research and Therapy*, **2019**, 14, 549-569	3.6	9
13	Application of novel nanotechnologies in asthma. *Annals of Translational Medicine*, **2020**, 8, 159	3.2	2
12	Emerging concepts and directed therapeutics for the management of asthma: regulating the regulators. *Inflammopharmacology*, **2021**, 29, 15-33	5.1	4
11	Nanoparticle Formulations and Delivery Strategies for Sustained Drug Release in the Lungs. **2021**, 273-300		
10	Medicinal Plant Based Advanced Drug Delivery System for the Treatment of Chronic Lung Diseases. **2021**, 583-608		
9	Testing of aerosolized ciprofloxacin nanocarriers on cystic fibrosis airway cells infected with P. aeruginosa biofilms. *Drug Delivery and Translational Research*, **2021**, 11, 1752-1765	6.2	3
8	Nanoparticle-Based Drug Delivery System: The Magic Bullet for the Treatment of Chronic Pulmonary Diseases. *Molecular Pharmaceutics*, **2021**, 18, 3671-3718	5.6	9

7	Therapeutic Benefits from Nanoparticles: The Potential Significance of Nanoscience in Retinal Degenerative Diseases. **2019**, 1, 44-55		
6	Mucus-producing epithelial models for investigating the activity of gene delivery systems in the lung.. *International Journal of Pharmaceutics*, **2021**, 614, 121423	6.5	0
5	Protective effects of adipose-derived biogenic nanoparticles on the pulmonary microvascular endothelial barrier in mice with ventilator-induced lung injury via the TRPV4/ROCK1 signalling pathway.. *Pulmonary Pharmacology and Therapeutics*, **2022**, 102123	3.5	0
4	Cell and Gene Therapies for Chronic Inflammatory Lung Diseases: Emerging Technological Trends and Advancements in Respiratory Medicine. **2022**, 539-559		
3	Pulmonary Delivery Nanomedicines Towards Circumventing Physiological Barriers: Strategies and Characterization Approaches.. *Advanced Drug Delivery Reviews*, **2022**, 114309	18.5	0
2	Recent advances in nanotechnology approach for non-viral gene therapy.		0
1	Utility of nanomedicine and nanocarriers for noninfectious disease treatment. **2023**, 207-223		0